XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
November 07, 2024 07:30 ET
|
XOMA Corporation
Zevra’s MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty’s portfolio XOMA Royalty acquired a 50 percent economic interest in TWIST Bioscience’s...
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
October 22, 2024 08:00 ET
|
XOMA Corporation
XOMA Royalty acquires 50% economic interest in portfolio of 60-plus early-stage assets with $15M payment to Twist Bioscience
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
September 23, 2024 06:30 ET
|
XOMA Corporation
MIPLYFFA(TM) becomes 6th commercial asset in XOMA Royalty's portfolio
XOMA Royalty Declares Quarterly Preferred Stock Dividends
September 23, 2024 05:30 ET
|
XOMA Corporation
October 2024 Dividends on Perpetual Preferred Shares
XOMA Royalty to Present at Upcoming Investor Conferences in September
September 04, 2024 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the...
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
August 13, 2024 07:30 ET
|
XOMA Corporation
Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolute Expanded the commercial royalty and milestone portfolio with the...
XOMA Declares Quarterly Preferred Stock Dividends
June 20, 2024 07:30 ET
|
XOMA Corporation
July 2024 Dividends
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
June 12, 2024 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from Viracta...
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
May 14, 2024 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C....
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
May 09, 2024 07:30 ET
|
XOMA Corporation
Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired...